secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001034842-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Rigel Pharmaceuticals Provides Preliminary Q4 2025 Revenue of $69.8M and 2026 Outlook of $275-290M
--------------------------------------------------------------------------------

- Preliminary Q4 2025 total revenue $69.8M, net product sales $65.4M, vs $57.6M and $46.5M in Q4 2024.
- Full year 2025 total revenue $294.3M, net product sales $232.0M, up 60% from 2024.
- 2026 outlook: total revenue $275-290M, net product sales $255-265M, positive net income expected.
- R289 Phase 1b study: RBC-TI achieved by 33% (6/18) evaluable patients at doses ≥500 mg QD; enrollment on track for RP2D selection H2 2026.
- FDA approved boxed warning for GAVRETO (pralsetinib) for serious infections; postmarketing commitment met.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000005/0001034842-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000005/rigl-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer